Evidence map›Paper›PMID 42010307›Full record

ReviewCell death & disease2026

Methodological guidelines for P2X receptor assays and data interpretation.

Dariusz C Gorecki, Elena Adinolfi, Sahil Adriouch, Robson Coutinho-Silva, Tobias Engel, Flóra Gölöncsér, Friedrich Haag, Peter Illes, Kenneth A Jacobson, Friedrich Koch-Nolte and 19 more

Abstract readReview
In one paragraph

Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Dariusz C GoreckiSchool of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. darek.gorecki@port.ac.uk.ORCID http://orcid.org/0000-0003-3584-1654
Elena AdinolfiDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0001-8129-9929
Sahil AdriouchUniv Rouen Normandie, INSERM, U1234, Pathophysiology Autoimmunity and Immunotherapy (PANTHER), Normandie Univ, Rouen, France.ORCID http://orcid.org/0000-0002-0265-7773
Robson Coutinho-SilvaLaboratório de Imunofisiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-7318-0204
Tobias EngelDepartment of Physiology & Medical Physics, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Flóra GölöncsérLaboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, Hungary.
Friedrich HaagInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-6555-3106
Peter IllesRudolf Boehm Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-0484-9389
Kenneth A JacobsonMolecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-8104-1493
Friedrich Koch-NolteInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0003-1730-6674
Steven E MansoorDepartment of Chemical Physiology & Biochemistry; Division of Cardiovascular Medicine, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0001-9606-8955
Carlos MatuteLaboratory of Neurobiology, Universidad del País Vasco (UPV/EHU), CIBERNED-Instituto Carlos III, IIS-Biobizkaia, Department of Neurosciences, School of Medicine and Nursing, Leioa, Spain.ORCID http://orcid.org/0000-0001-8672-711X
Gerry MelinoUniversity of Rome "Tor Vergata", Rome, Italy.ORCID http://orcid.org/0000-0001-9428-5972
Ivana NovakDepartment of Biology, Universitetsparken 13, University of Copenhagen, Copenhagen Ø, Denmark.ORCID http://orcid.org/0000-0002-8917-8010
Anna PegoraroDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Pablo PelegrinDepartment of Biochemistry and Molecular Biology and Immunology, Faculty of Medicine, University of Murcia, BioMedical Research Institute of Murcia, Murcia, Spain.ORCID http://orcid.org/0000-0002-9688-1804
Mauro PiacentiniUniversity of Rome "Tor Vergata", Rome, Italy.ORCID http://orcid.org/0000-0003-2919-1296
Simon C RobsonDepartments of Anesthesia and Medicine, CLS 612, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6374-0194
Robin M H RumneyBone and Joint Group, School of Human Development and Health, Faculty of Medicine, University Hospital Southampton, University of Southampton, Southampton, England.
Michel SemanUniv Rouen Normandie, INSERM, U1234, Pathophysiology Autoimmunity and Immunotherapy (PANTHER), Normandie Univ, Rouen, France.
Ronald SluyterMolecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.ORCID http://orcid.org/0000-0003-4909-686X
Beáta SperlaghLaboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, Hungary.
Yong TangInternational Joint Research Centre on Purinergic Signalling, School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China.ORCID http://orcid.org/0000-0002-2543-066X
Mario TarantiniInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Henning UlrichDepartamento de Bioquimica, Instituto de Quimica Universidade de Sao Paulo, Sao Paulo, Brazil.ORCID http://orcid.org/0000-0002-2114-3815
Valerie Vouret-CraviariUniversité Côte d'Azur, CNRS, UMR7284, INSERM, U1081, IRCAN, Nice, France & IHU RespirERA, Nice, France.ORCID http://orcid.org/0000-0003-4096-5926
Qing YeInternational Joint Research Centre on Purinergic Signalling, School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Gennady G YegutkinMediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland.
Alexei VerkhratskyFaculty of Biology, Medicine, and Health, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-2592-9898

Funding

Elucidation of P2X7 Receptor Signaling and Development of Novel Small Molecule and Aptamer Ligand TherapiesDP2GM149551 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI MANSOOR, STEVEN ELIAS · 2022 to 2025
$2.3M
Purinergic ThromboregulationR01HL094400 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2009 to 2010
$1.4M
NHLBI NIH HHS R01 HL094400NIGMS NIH HHS DP2 GM149551
6 · The paper itself

Abstract

P2X receptors (P2XR) are a family of seven cation channels gated by extracellular ATP (eATP). Activation of P2XRs results in diverse cellular responses, including cell signalling, proliferation, differentiation, and death-all critically important in multiple physiological and pathophysiological states. These receptors, therefore, represent therapeutic targets of considerable interest. However, P2XRs, while structurally related, exhibit highly divergent and context-dependent functions. Their spatiotemporal and functional complexity is evident by overlapping expression across multiple cell types that can shift dynamically during physiological processes or disease progression. Furthermore, P2XRs can assemble as homo- or hetero-trimers, with distinct functional properties. These factors complicate definitive identification of a given P2XR responsible for a specific pathophysiological effect. Receptor activity in vivo is transient because of receptor-specific mechanisms and follows eATP breakdown by ectonucleotidases. Any correlation of ATP release with receptor engagement, as assessed in vitro, often does not correspond with the in vivo dynamics. Translation from animal models to humans is complicated by the species-specific pharmacology of some P2XRs, confounded by many animal models in use not fully replicating human P2XR function and regulation in pathology. Furthermore, there are no clinical biomarkers to distinguish incomplete receptor blockade from lack of therapeutic effect. Thus, translation has been very limited. To identify and validate specific P2XR functionalities, future experimental designs should use approaches and assays that can reliably assess receptor involvement, while reducing methodologically flawed findings. We propose guidelines developed in consultation with the purinergic community for consistent and reliable research practices in P2XR studies.

Indexed as

Receptors, Purinergic P2XAdenosine TriphosphateAnimalsBiomarkersHumansSignal TransductionAdenosine TriphosphateBiomarkersReceptors, Purinergic P2X

Identifiers

PMID42010307
PMCPMC13230957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.